Orkambi
| Chemical Name | lumacaftor/ivacaftor |
| Dosage Form | Tablet (oral; lumacaftor mg/ivacaftor mg: 100 mg/125 mg, 200 mg/125 mg); granules (oral; lumacaftor mg/ivacaftor mg: 100 mg/125 mg, 150 mg/188 mg) |
| Drug Class | CFTR potentiators |
| System | Respiratory |
| Company | Vertex Pharms Inc |
| Approval Year | 2015 |
Indication
- For the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.
Last updated on 10/29/2020